Lyra Therapeutics Inc (LYRA) - Cash Flow Conversion Efficiency
Based on the latest financial reports, Lyra Therapeutics Inc (LYRA) has a cash flow conversion efficiency ratio of 0.566x as of December 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($-6.07 Million) by net assets ($-10.72 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. Also see market value of Lyra Therapeutics Inc for the company's overall valuation and market capitalisation.
Lyra Therapeutics Inc - Cash Flow Conversion Efficiency Trend (2018–2025)
This chart illustrates how Lyra Therapeutics Inc's cash flow conversion efficiency has evolved over time, based on yearly financial data.
Lyra Therapeutics Inc Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Lyra Therapeutics Inc ranked by their cash flow conversion efficiency. See debt repayment capacity of Lyra Therapeutics Inc to evaluate how effectively operating cash flow covers total debt obligations.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Hercules Site Services PLC
LSE:HERC
|
0.120x |
|
Predator Oil & Gas Holdings Plc
LSE:PRD
|
-0.067x |
|
Ortivus AB ser. A
ST:ORTI-A
|
0.074x |
|
Dewhurst
LSE:DWHT
|
0.062x |
|
Amigo Holdings PLC
LSE:AMGO
|
N/A |
|
China Liberal Education Holdings
NASDAQ:CLEU
|
-0.015x |
|
PBT Group Ltd
JSE:PBG
|
0.295x |
|
Glob Bioenergi
PA:ALGBE
|
-3.463x |
Annual Cash Flow Conversion Efficiency for Lyra Therapeutics Inc (2018–2025)
The table below shows the annual cash flow conversion efficiency of Lyra Therapeutics Inc from 2018 to 2025. View current stock price of Lyra Therapeutics Inc for real-time trading data and today's change.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2025-12-31 | $-10.72 Million | $-28.86 Million | 2.693x | +144.59% |
| 2024-12-31 | $11.59 Million | $-70.01 Million | -6.039x | -752.98% |
| 2023-12-31 | $89.42 Million | $-63.30 Million | -0.708x | -31.77% |
| 2022-12-31 | $80.75 Million | $-43.38 Million | -0.537x | +28.60% |
| 2021-12-31 | $34.32 Million | $-25.82 Million | -0.752x | -165.10% |
| 2020-12-31 | $74.49 Million | $-21.14 Million | -0.284x | +84.88% |
| 2019-12-31 | $7.33 Million | $-13.75 Million | -1.877x | -3126.63% |
| 2018-12-31 | $-107.07 Million | $-6.64 Million | 0.062x | -- |
About Lyra Therapeutics Inc
Lyra Therapeutics, Inc., a clinical-stage biotechnology company, focuses on the development and commercialization of anti-inflammatory therapies for the treatment of patients with chronic rhinosinusitis. Its technology is designed to deliver medicines directly to the affected tissue for sustained periods with a single administration. The company's product candidates include LYR-210, an anti-infla… Read more